Business Information
The group's principal activities is to focus on the development of cells, medical products and associated research and development activities. The group has two subsidiaries, multicell technologies, inc and xenogenics corporation. Multicell develops, sells and licenses hepatic or liver cells, cell lines, and associated products to be used in drug development, diagnostic and therapeutic applications. Xenogenics develops sybiol(R) bio-synthetic liver device, the key product of the group, which will not be ready to be marketed before the end of the year 2006, at the earliest. On 24-Mar-2004, the group acquired exten industries inc.
|
|
Name |
Title
|
Email
|
| Gerald Newmin | Chmn., Acting CFO | N/A | | Alan Tuchman | Member - Scientific Advisory Board | N/A | | Anthony Altig | Dir. | N/A | | Douglas Hixson | Member - Scientific Advisory Board | N/A | | Edward Maggio | Member - Scientific Advisory Board | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 680 | (5,418) | | 2005 | 209 | (5,683) | | 2004 | 760 | (1,739)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
